Display Settings:

Format

Send to:

Choose Destination
    Chem Biol. 2010 May 28;17(5):471-82.

    Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.

    Source

    Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

    Abstract

    The histone acetyltransferase (HAT) p300/CBP is a transcriptional coactivator implicated in many gene regulatory pathways and protein acetylation events. Although p300 inhibitors have been reported, a potent, selective, and readily available active-site-directed small molecule inhibitor is not yet known. Here we use a structure-based, in silico screening approach to identify a commercially available pyrazolone-containing small molecule p300 HAT inhibitor, C646. C646 is a competitive p300 inhibitor with a K(i) of 400 nM and is selective versus other acetyltransferases. Studies on site-directed p300 HAT mutants and synthetic modifications of C646 confirm the importance of predicted interactions in conferring potency. Inhibition of histone acetylation and cell growth by C646 in cells validate its utility as a pharmacologic probe and suggest that p300/CBP HAT is a worthy anticancer target.

    2010 Elsevier Ltd. All rights reserved.

    PMID:
    20534345
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2884008
    Free PMC Article

    Images from this publication.See all images (7) Free text

    Figure 1
    Figure 3
    Figure 5
    Figure 2
    Figure 4
    Figure 6

      Supplemental Content

      Icon for Elsevier Science Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk